Use of human papillomavirus vaccines among young adult women in the United States: An analysis of the 2008 National Health Interview Survey

Cancer

Volumn 117, Issue 24, 2011, Pages 5560-5568

  Anhang Price, Rebecca ^a   Tiro, Jasmin A ^b   Saraiya, Mona ^c   Meissner, Helen ^d   Breen, Nancy ^e  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cervical cancer; disparities; human papillomavirus; vaccines

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; AWARENESS; CANCER RISK; DEMOGRAPHY; DRUG USE; FEMALE; HEALTH CARE ACCESS; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SOCIAL ASPECT; SOCIAL STATUS; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION;

ADOLESCENT; ADULT; FEMALE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTHCARE DISPARITIES; HUMANS; IMMUNIZATION; PAPILLOMAVIRUS VACCINES; UNITED STATES; YOUNG ADULT;

EID: 82955212820     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26244     Document Type: Article

References (40)

1. US Food and Drug Administration. FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. Accessed June 8, 2010.
2. US Food and Drug Administration. FDA approves new vaccine for prevention of cervical cancer. Accessed June 8, 2010.
3. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR,. Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Cancer. 2009; 19: 1166-1176.
4. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102: 325-339.
5. Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009; 374: 1975-1985.
6. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER,. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56: 1-24.
7. Broder KR, Cohn AC, Schwartz B, et al. Adolescent immunizations and other clinical preventive services: a needle and a hook? Pediatrics. 2008; 121 (suppl 1): S25-S34.
8. Recommended immunization schedules for persons aged 0 through 18 years-United States, 2010. MMWR Recomm Rep. 2010; 58: 1-4.
9. Kim JJ, Goldie SJ,. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008; 359: 821-832.
10. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance-United States, 2007. MMWR Surveill Summ. 2008; 57: 1-131.
11. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297: 813-819. (Pubitemid 46333946)
12. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356: 1928-1943. (Pubitemid 46740303)
13. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007; 298: 743-753. (Pubitemid 47263157)
14. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356: 1915-1927.
15. Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009; 5: 696-704.
16. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342-362. (Pubitemid 35446606)
17. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 3rd ed. Washington, DC: U.S. Department of Health and Human Services; 2003.
18. ACOG practice bulletin no. 109: cervical cytology screening. Obstet Gynecol. 2009; 114: 1409-1420.
19. ACOG Committee Opinion No. 344: Human papillomavirus vaccination. Obstet Gynecol. 2006; 108: 699-705.
20. Prevention of human papillomavirus infection: provisional recommendations for immunization of girls and women with quadrivalent human papillomavirus vaccine. Pediatrics. 2007; 120: 666-668.
21. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007; 57: 7-28. (Pubitemid 46148088)
22. Watson M, Saraiya M, Wu X,. Update of HPV-associated female genital cancers in the United States, 1999-2004. J Womens Health (Larchmt). 2009; 18: 1731-1738.
23. McDougall JA, Madeleine MM, Daling JR, Li CI,. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003. Cancer Causes Control. 2007; 18: 1175-1186. (Pubitemid 47498166)
24. Benard VB, Johnson CJ, Thompson TD, et al. Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. Cancer. 2008; 113 (10 suppl): 2910-2918.
25. Brookfield KF, Cheung MC, Lucci J, Fleming LE, Koniaris LG,. Disparities in survival among women with invasive cervical cancer: a problem of access to care. Cancer. 2009; 115: 166-178.
26. Singh GK, Miller BA, Hankey BF, Edwards BK,. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer. 2004; 101: 1051-1057. (Pubitemid 39100440)
27. Freeman HP, Wingrove BK,. Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities. Rockville, MD: National Cancer Institute, Center to Reduce Cancer Health Disparities; May 2005.
28. Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L,. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev Med. 2009; 48: 426-431.
29. Chao C, Velicer C, Slezak JM, Jacobsen SJ,. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol. 2010; 171: 357-367.
30. National Center for Health Statistics. 2008 National Health Interview Survey (NHIS) Public Use Data Release: NHIS Survey Description. Accessed June 8, 2010.
31. Caskey R, Lindau ST, Alexander GC,. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health. 2009; 45: 453-462.
32. Jain N, Stokley S, Yankey D,. Vaccination coverage among adolescents aged 13-17 years-United States, 2007. MMWR Morb Mortal Wkly Rep. 2008; 57: 1100-1103.
33. Stokley S, Dorell C, Yankey D,. National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2008. MMWR Morb Mortal Wkly Rep. 2009; 58: 997-1001.
34. National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2009. MMWR Morb Mortal Wkly Rep. 2010; 59: 1018-1023.
35. Rosenthal SL, Weiss TW, Zimet GD, Ma L, Good MB, Vichnin MD,. Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation. Vaccine. 2011; 29: 890-895.
36. Khan K, Curtis CR, Ekwueme DU, et al. Preventing cervical cancer: overviews of the National Breast and Cervical Cancer Early Detection Program and 2 US immunization programs. Cancer. 2008; 113 (10 suppl): 3004-3012.
37. Hewitt M, Devesa SS, Breen N,. Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey. Prev Med. 2004; 39: 270-278. (Pubitemid 38834016)
38. Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005; 97: 675-683. (Pubitemid 40812631)
39. Merck Vaccine Patient Assistance Program. Accessed June 8, 2010.
40. Wong C, Berkowitz Z, Dorell C, Anhang Price R, Lee J, Saraiya M,. National HPV vaccine uptake among pre-adolescent and adolescent girls-National Health Interview Survey, United States, 2008 Cancer. 2011; 00: 000-000.